- $883.39m
- $813.37m
Brief: Alpha Tau Announces 100% Local Disease Control Rate And Favorable Safety Profile Observed In Alpha Dart® Pancreatic Cancer Trials Presented At Ddw 2026
Brief: Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Alpha Tau Announces First-Ever Oral Presentation Of Alpha Dart® Pancreatic Cancer Data At Digestive Disease Week (Ddw) 2026
Brief: Alpha Tau Medical Receives Japanese Marketing Approval For Alpha Dart In Head And Neck Cancer
Brief: Alpha Tau Reports New Positive Results In Two Upcoming Presentations
Brief: Alpha Tau Submits First Pre-Market Approval Module To The FDA
Brief: Alpha Tau Receives FDA Approval To Initiate A Trial For Patients With Locally Recurrent Prostate Cancer
Brief: Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
Brief: Oramed Pharmaceuticals Announces $36.9 Million Investment And Strategic Collaboration With Alpha Tau Medical
Brief: Alpha Tau Receives FDA Approval To Initiate A Trial For Patients With Recurrent Glioblastoma
Brief: Alpha Tau Medical Announces Third Quarter 2024 Financial Results
Brief: Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program To Accelerate Market Access To Alpha Dart® For Patients With Recurrent Glioblastoma Multiforme
Brief: Alpha Tau Medical Announces Q1 2024 Financial
Brief: Alpha Tau Announces Highly Promising Interim Results From Safety And Feasibility Trial Of Alpha Dart Treatment Of Advanced Pancreatic Cancer
Brief: Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
Brief: Alpha Tau Medical Announces Third Quarter 2023 Financial Results
Brief: Alpha Tau Enters Into Long-Term Lease Of Site In New Hampshire
Brief: Alpha Tau Treats First Patient With Advanced Inoperable Pancreatic Cancer
U.S. STOCKS ON THE MOVE-Estee Lauder, Xpeng, Ross Stores